Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05775367

Cochlear Implants in Young Children With SSD

The goal of this clinical trial is to investigate the safety and effectiveness of cochlear implantation in infants and toddlers with single-sided deafness.

The main questions it aims to answer are:

* Are cochlear implants an effective treatment of single-sided deafness in infants and toddlers? * Are cochlear implants a safe treatment for single-sided deafness in infants and toddlers?

Participants will receive a cochlear implant and be followed until they are five years old. During those five years, the investigators will program the device and monitor auditory development.

Children will be asked to:

* Undergo cochlear implantation * Wear their cochlear implant processor whenever they are awake. * Participate in traditional hearing tests * Participate in traditional hearing testing * Participate in localization testing * Participate in hearing in noise testing * Participate in word recognition testing * Participate in speech, language, and educational evaluations

The researchers will compare results to children with typical hearing in both ears and children with single-sided deafness who have not received an implant to observe any differences between the groups.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 month–71 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Children's Cochlear Implant Center at UNC

Durham, North Carolina, 27713, United States

Location status: Recruiting

Location contact

A. Morgan Selleck, MD

SUB_INVESTIGATOR

CI Research

CONTACT

[email protected]

Caitlin Sapp, AuD, PhD

SUB_INVESTIGATOR

Carlton Zdanski, MD

SUB_INVESTIGATOR

Dakota Sharp, AuD

SUB_INVESTIGATOR

Erika Gagnon, AuD

SUB_INVESTIGATOR

Erin Thompson, MS

SUB_INVESTIGATOR

Jennifer Woodard, AuD

SUB_INVESTIGATOR

Kevin Brown, MD, PhD

PRINCIPAL_INVESTIGATOR

Lauren Leeper, MD

SUB_INVESTIGATOR

Lillian Henderson, MSP

SUB_INVESTIGATOR

Lisa Park, AuD

CONTACT

[email protected]

984-215-2871

Lisa Park, AuD

PRINCIPAL_INVESTIGATOR

Margaret Richter, AuD

SUB_INVESTIGATOR

Matthew Dedmon, MD, PhD

SUB_INVESTIGATOR

Melissa Anderson, AuD

SUB_INVESTIGATOR

Meredith Rooth, AuD

SUB_INVESTIGATOR

Samantha Scharf, AuD

SUB_INVESTIGATOR

Sandra Hancock, MS

SUB_INVESTIGATOR

Sarah Spencer, MS

SUB_INVESTIGATOR

About this study

Cochlear implantation is an FDA-approved option for children with single-sided deafness (SSD) who are over the age of five years. It has been well established that early implantation is advantageous for children with bilateral hearing loss as it takes advantage of the narrow window of neural plasticity. Research has yet to show the ideal age for implantation in children with SSD but considering the known impacts of age at implantation and duration of deafness on cochlear implant (CI) outcomes, five years is likely a late age for implantation in a child with congenital SSD. The purpose of this prospective clinical trial is to evaluate the safety and effectiveness of cochlear implantation in infants and toddlers with SSD.

Twenty (20) infants and Toddlers with SSD who are under the age of three will receive a cochlear implant. They will be followed until they reach the age of five. A group of typically hearing five-year-olds (n=20) and a group of five-year-olds with congenital or early onset SSD who have not received a cochlear implant (n=20) will also be recruited. All three groups of five-year-olds will be tested on measures of hearing in quiet, localizing, and hearing in spatially separated noise for comparison. Scores from the study group and the SSD control group will be compared to evaluate effectiveness.

The study will also explore the potential effects of SSD and early implantation on language, sensory processing, executive function, fatigue, and cognition.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

To be eligible to participate in this trial as a study subject, an individual must meet all of the following criteria:

  • Provision of signed and dated parental permission form
  • Unilateral severe-to-profound sensorineural hearing loss, congenital or acquired prior to the age of 2 years, defined as:
  • Unaided residual hearing thresholds that yield a 3 frequency pure tone average (PTA; average at 500, 1000, and 2000 Hz) of ≥70 dB hearing loss (HL) in the ear to be implanted
  • Hearing thresholds in the contralateral ear of ≤20 dB HL (3 frequency PTA of 500, 1000, and 2000 Hz).

i. Thresholds should be measured using inserts wherever possible, or in the sound field to record the better-hearing ear alone. Required thresholds will include 250, 500, 1000, 2000, and 4000 Hz for air conduction. All other octave frequencies should be attempted. Bone conduction thresholds should be obtained at 500, 1000, 2000, and 4000 Hz. Masking should be attempted where appropriate. As participants are very young and masking is difficult for this population, suspected shadow audiograms will be sufficient if objective testing has confirmed a severe-to-profound unilateral hearing loss. Testing should confirm a severe-to-profound hearing loss, defined as a 3-frequency PTA (500, 1000, and 2000) >70 dB HL in one ear and ≤20 dB HL in the contralateral ear. The Primary Investigator and Lead Diagnostic Audiologist must agree on this diagnosis for enrollment.

  • Insufficient functional access to sound with appropriately fit amplification and aural habilitation (based on best practices and standard of care) defined as:
  • PEACH + parent questionnaire scores below the expected value for children who lack the requisite language to complete open-set word recognition testing or
  • Recorded Multisyllabic Lexical Neighborhood Test (MLNT) scores ≤ 30% in the ear to be implanted for children with the requisite language to complete open-set word recognition testing.
  • Between 7 months and 2 years, 11 months of age at implantation
  • Normal cochlear nerve as evaluated by imaging, required imaging by MRI brain/Internal auditory canal (IAC) without contrast with heavily weighted T2 images. CT optional at the physician's discretion.
  • No malformation of the cochlea
  • No evidence of progressive hearing loss of the contralateral ear
  • Willing to/has undergone hearing aid trial as warranted based on achieving an aided speech intelligibility index (SII) of > .65 when fitted via Desired Sensation Level (DSL) methods.
  • Realistic parental expectations: a verbal acknowledgment of the potential benefits and risks, and postoperative variation in performance. For instance, cochlear implantation will not restore normal hearing
  • Willing to obtain recommended meningitis vaccinations per Centers for Disease Control (CDC) recommendations
  • Development and cognition within the normal range as measured by the Developmental Assessment of Young Children (DAYC-2).
  • Parental commitment to study parameters including being able and willing to participate in the evaluation schedule, involvement in prescribed therapy, and travel to the investigational site and study-related activities. Parents must be willing to encourage wearing implant during waking hours.

To participate as an SSD control subject, an individual must meet all the following criteria:

  • Provision of signed and dated parental permission form
  • Unilateral severe-to-profound hearing loss - congenital or acquired prior to 2 years of age.
  • Unaided residual hearing thresholds that yield a 3 frequency PTA (500, 1000, and 2000 Hz) of ≥70 dB HL in the affected ear.
  • Hearing thresholds in the contralateral ear of ≤20 dB HL (3 frequency PTA of 500, 1000, and 2000 Hz)
  • Unable to use or benefit from traditional amplification
  • Five years of age at the time of testing
  • Development and cognition within the normal range as measured by the Early Stanford Binet 2 (SB2).

To participate as a TH control subject, an individual must meet all the following criteria:

  • Provision of signed and dated parental permission form
  • Bilateral hearing thresholds that yield a PTA of ≤20 dB HL (3 frequency PTA of 500, 1000, and 2000 Hz).
  • Five years of age at the time of testing
  • Development and cognition within the normal range as measured by the Early SB2.

An individual who meets any of the following criteria will be excluded from participation in this study as a study subject:

  • English is not primary language of the home
  • Speech perception materials are presented in English
  • Parental questionnaires are administered in English
  • Conductive hearing loss in either ear
  • Cochlear nerve deficiency
  • Ossification/Fibrosis of the cochlea precluding implantation
  • Inability to participate in follow-up procedures (i.e., unwillingness, geographic location)
  • History of refractory chronic otitis media or condition that contraindicates anesthesia

An individual who meets any of the following criteria will be excluded from participation in this study as a control subject:

  • English is not primary language of the home
  • Speech perception materials are presented in English
  • Parental questionnaires are administered in English
  • Inability to participate in testing (i.e., unwillingness)

Treatment and study plan

Cochlear Implant

Device

A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.

Other names: MED-EL SYNCHRONY 2 Cochlear Implant

Primary outcomes

  1. Mean Difference in the Signal-to-Noise Ratio 50 (SNR-50) between the Study Group and SSD Control Group as Measured with the BKB-SIN at 5 Years of Age

    Time frame: 5 years of age

    Two ½ lists of the Bamford-Kowal-Bench Speech in Noise Test (BKB-SIN) will be presented in a single condition: speech in front and masker directed 90 degrees to the normal ear. The SNR-50 represents the signal-to-noise ratio required to perceive 50% of the sentence. A lower score is better. All participants will be 5 years old at the time of testing. The study group will use their cochlear implant in conjunction with the normal hearing ear. The SSD control group will use their normal hearing ear alone.

  2. Mean Difference in Localization Error Between the Study Group and the SSD Control group Measured at 5 Years of Age

    Time frame: 5 years of age

    Soundfield localization of 200-ms speech-shaped noise, presented from 11 speakers at 70 decibel (dB) sound pressure level (SPL) in a sound treated room. Overall root-mean-square (RMS) error is the difference between the sound source azimuth and the response azimuth and a lower score indicates more accurate localization of the sound source. All participants will be 5 years old at the time of testing. The study group will use their cochlear implant in conjunction with the normal hearing ear. The SSD control group will use their normal hearing ear alone.

Secondary outcomes

  1. Proportion of Procedural Related Adverse Events 6 months after Surgery

    Time frame: 6 months after surgery

    Procedural adverse events will be collected and reported as the proportion of subjects experiencing them.

  2. Proportion of Device-Related Adverse Events 6 Months after Surgery

    Time frame: 6 months after surgery

    Device related adverse events will be collected and reported as the proportion of subjects experiencing them.

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa Park, AuD

CONTACT

[email protected]

9842152871

Study Coordinator

CONTACT

[email protected]

919-966-5251

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Med-El Corporation

Registry information

Official study title

Cochlear Implantation in Infants and Toddlers With Single-Sided Deafness

Acronym: Little SSD

Important dates

Study start
2023
Primary completion
2030
Study completion
2030
First posted
Mar 20, 2023
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.